Revealing cancer driver genes through integrative transcriptomic and epigenomic analyses with Moonlight

TL;DR

This paper introduces a new method to identify cancer driver genes by combining gene expression and DNA methylation data, revealing insights into three cancer types.

Contribution

The novel Gene Methylation Analysis (GMA) functionality in Moonlight2 integrates DNA methylation data to predict epigenetically driven cancer genes.

Findings

GMA identified 33, 190, and 263 epigenetically driven genes in basal-like breast cancer, lung adenocarcinoma, and thyroid carcinoma, respectively.

Some of the identified driver genes showed prognostic effects and therapeutic potential as drug targets.

The study provides a framework for understanding cancer progression by integrating gene expression and methylation data.

Abstract

Cancer involves dynamic changes caused by (epi)genetic alterations such as mutations or abnormal DNA methylation patterns which occur in cancer driver genes. These driver genes are divided into oncogenes and tumor suppressors depending on their function and mechanism of action. Discovering driver genes in different cancer (sub)types is important not only for increasing current understanding of carcinogenesis but also from prognostic and therapeutic perspectives. We have previously developed a framework called Moonlight which uses a systems biology multi-omics approach for prediction of driver genes. Here, we present an important development in Moonlight2 by incorporating a DNA methylation layer which provides epigenetic evidence for deregulated expression profiles of driver genes. To this end, we present a novel functionality called Gene Methylation Analysis (GMA) which investigates abnormal DNA methylation patterns to predict driver genes. This is achieved by integrating the tool EpiMix which is designed to detect such aberrant DNA methylation patterns in a cohort of patients and further couples these patterns with gene expression changes. To showcase GMA, we applied it to three cancer (sub)types (basal-like breast cancer, lung adenocarcinoma, and thyroid carcinoma) where we discovered 33, 190, and 263 epigenetically driven genes, respectively. A subset of these driver genes had prognostic effects with expression levels significantly affecting survival of the patients. Moreover, a subset of the driver genes demonstrated therapeutic potential as drug targets. This study provides a framework for exploring the driving forces behind cancer and provides novel insights into the landscape of three cancer sub(types) by integrating gene expression and methylation data.

Cancer is a complex disease and a main cause of mortality worldwide. This heterogeneous disease arises due to accumulation of changes which occur in driver genes that drive cancer progression when they are altered. These driver genes are commonly divided into oncogenes, which promote cancer, and tumor suppressors, which prevent it. A major goal of cancer research is identifying these driver genes, crucial for increasing our current understanding of cancer biology and for developing novel treatment approaches. A large number of cancer driver genes have already been identified. However, the underlying mechanisms for the alterations in these genes is challenging to predict given their context-dependent behavior and the complexity of cancer. Such explanations are the focus of this study with the aim of providing evidence of why certain genes do not function normally in cancer. Within this context, we present a new functionality to our previously developed cancer driver predictive framework, Moonlight. This new functionality integrates multiple data types to predict oncogenes and tumor suppressors in a systems-biology-oriented manner that is freely available as a R package for the community.

Figures